{
  "success": true,
  "pagesUsed": [
    7,
    8,
    9,
    36,
    37,
    38,
    39,
    40,
    41,
    42,
    43,
    45,
    46,
    47
  ],
  "modelUsed": "gemini-3-flash-preview",
  "eligibility": {
    "eligibilityCriterionItems": [
      {
        "id": "eci_1",
        "name": "Age requirement",
        "text": "Adult male or female, at least ≥ 18 years old at Screening.",
        "instanceType": "EligibilityCriterionItem"
      },
      {
        "id": "eci_2",
        "name": "PsA Diagnosis and CASPAR",
        "text": "Clinical diagnosis of PsA with symptom onset at least 6 months prior to the Screening Visit and fulfillment of the Classification Criteria for PsA (CASPAR).",
        "instanceType": "EligibilityCriterionItem"
      },
      {
        "id": "eci_3",
        "name": "Active Disease at Baseline",
        "text": "Subject has active disease at Baseline defined as ≥ 3 tender joints (based on 68 joint counts) and ≥ 3 swollen joints (based on 66 joint counts) at Screening and Baseline Visits.",
        "instanceType": "EligibilityCriterionItem"
      },
      {
        "id": "eci_4",
        "name": "Plaque Psoriasis History",
        "text": "Diagnosis of active plaque psoriasis or documented history of plaque psoriasis.",
        "instanceType": "EligibilityCriterionItem"
      },
      {
        "id": "eci_5",
        "name": "bDMARD Inadequate Response",
        "text": "Subject has had an inadequate response (lack of efficacy after a minimum 12 week duration of therapy) or intolerance to treatment with at least 1 bDMARD.",
        "instanceType": "EligibilityCriterionItem"
      },
      {
        "id": "eci_6",
        "name": "bDMARD Discontinuation",
        "text": "Subjects must have discontinued all bDMARDs prior to the first dose of study drug. Subjects who need to discontinue bDMARDs prior to the Baseline Visit to comply with this inclusion criterion must follow the procedure specified below or at least five times the mean terminal elimination half-life of a drug: ≥ 4 weeks for etanercept; ≥ 8 weeks for adalimumab, infliximab, certolizumab, golimumab, abatacept, tocilizumab, and ixekizumab; ≥ 16 weeks for secukinumab; ≥ 12 weeks for ustekinumab; ≥ 1 year for rituximab OR ≥ 6 months if B cells have returned to pretreatment level or normal reference range (local lab) if pretreatment levels are not available.",
        "instanceType": "EligibilityCriterionItem"
      },
      {
        "id": "eci_7",
        "name": "Concomitant non-biologic DMARDs",
        "text": "Subject who is on current treatment with concomitant non-biologic DMARDs at study entry must be on ≤ 2 non-biologic DMARDs (except the combination of MTX and leflunomide) at the following doses: MTX (≤ 25 mg/week), SSZ (≤3000 mg/day), leflunomide (LEF) (≤20 mg/day), apremilast (≤60 mg/day), HCQ (≤ 400 mg/day), bucillamine (≤300 mg/day) and iguratimod (≤50 mg/day) for ≥ 12 weeks and at stable dose for ≥4 weeks prior to the Baseline Visit. No other DMARDs are permitted during the study.",
        "instanceType": "EligibilityCriterionItem"
      },
      {
        "id": "eci_8",
        "name": "Stable NSAIDs/Corticosteroids",
        "text": "Stable doses of NSAIDs, acetaminophen/paracetamol, low-potency opiates (tramadol or combination of acetaminophen and codeine or hydrocodone), oral corticosteroids (equivalent to prednisone ≤ 10 mg/day), or inhaled corticosteroids for stable medical conditions are allowed, but must have been at a stable dose for ≥1 weeks prior to the Baseline Visit.",
        "instanceType": "EligibilityCriterionItem"
      },
      {
        "id": "eci_9",
        "name": "Opiate and TCM Discontinuation",
        "text": "Subjects must have discontinued all opiates (except for tramadol or combination of acetaminophen and codeine or hydrocodone) at least 1 week and oral Traditional Chinese Medicine for at least 4 weeks prior to the first dose of study drug.",
        "instanceType": "EligibilityCriterionItem"
      },
      {
        "id": "eci_10",
        "name": "Pregnancy Test",
        "text": "Women of childbearing potential, must not have a positive serum pregnancy test at the Screening Visit and must have a negative urine pregnancy test at the Baseline Visit prior to study drug dosing.",
        "instanceType": "EligibilityCriterionItem"
      },
      {
        "id": "eci_11",
        "name": "Contraception Requirement",
        "text": "If female, subject must be postmenopausal OR permanently surgically sterile OR for Women of Childbearing Potential practicing at least one protocol specified method of birth control, that is effective from the Baseline visit through at least 30 days after the last dose of study drug.",
        "instanceType": "EligibilityCriterionItem"
      },
      {
        "id": "eci_12",
        "name": "Informed Consent",
        "text": "Subjects must voluntarily sign and date an informed consent, approved by an Independent Ethics Committee (IEC)/Institutional Review Board (IRB), prior to the initiation of any screening or study-specific procedures.",
        "instanceType": "EligibilityCriterionItem"
      },
      {
        "id": "eci_13",
        "name": "JAK Inhibitor Exposure",
        "text": "Prior exposure to any Janus Kinase (JAK) inhibitor (including but not limited to ruxolitinib, tofacitinib, baricitinib, and filgotinib).",
        "instanceType": "EligibilityCriterionItem"
      },
      {
        "id": "eci_14",
        "name": "Excessive DMARDs",
        "text": "Current treatment with > 2 non-biologic DMARDs or use of DMARDs other than MTX, SSZ, LEF, apremilast, HCQ, bucillamine or iguratimod or use of MTX in combination with LEF at Baseline.",
        "instanceType": "EligibilityCriterionItem"
      },
      {
        "id": "eci_15",
        "name": "Investigational Drug Use",
        "text": "Has been treated with any investigational drug within 30 days or five half-lives of the drug (whichever is longer) prior to the first dose of study drug or is currently enrolled in another interventional clinical study.",
        "instanceType": "EligibilityCriterionItem"
      },
      {
        "id": "eci_16",
        "name": "Infection History",
        "text": "Current or past history of infection including: History of recurrent or disseminated (even a single episode) herpes zoster; History of disseminated (even a single episode) herpes simplex; History of known invasive infection (e.g., listeriosis and histoplasmosis); Active human immunodeficiency virus (HIV) or immunodeficiency syndrome; Subject has active TB or meets TB exclusionary parameters; Active infection(s) requiring treatment with parenteral anti-infectives within 30 days, or oral anti-infectives within 14 days prior to the Baseline Visit; Chronic recurring infection and/or active viral infection; Active HBV or HCV.",
        "instanceType": "EligibilityCriterionItem"
      },
      {
        "id": "eci_17",
        "name": "Underlying Medical Diseases",
        "text": "Underlying medical diseases or problems including but not limited to: History of cardiovascular conditions (recent CVA, MI, stenting, uncontrolled hypertension); Organ transplant recipient; History of gastrointestinal perforation, diverticulitis; Conditions interfering with drug absorption; History of malignancy except NMSC or CIS of cervix; Clinically significant medical conditions; Wheelchair-bound or bedridden.",
        "instanceType": "EligibilityCriterionItem"
      },
      {
        "id": "eci_18",
        "name": "Psoriasis Treatments",
        "text": "Use of concomitant psoriasis treatments within specified timeframe: Phototherapy (4 weeks), Laser therapy (4 weeks), Topical psoriasis treatments (2 weeks).",
        "instanceType": "EligibilityCriterionItem"
      },
      {
        "id": "eci_19",
        "name": "Other Inflammatory Diseases",
        "text": "History of fibromyalgia, any arthritis with onset prior to age 17 years, or current diagnosis of inflammatory joint disease other than PsA (including, but not limited to rheumatoid arthritis, gout, overlap connective tissue diseases, scleroderma, polymyositis, dermatomyositis, systemic lupus erythematosus).",
        "instanceType": "EligibilityCriterionItem"
      },
      {
        "id": "eci_20",
        "name": "Drug or Alcohol Abuse",
        "text": "History of clinically significant (per Investigator's judgment) drug or alcohol abuse within the last 6 months preceding the Baseline Visit.",
        "instanceType": "EligibilityCriterionItem"
      },
      {
        "id": "eci_21",
        "name": "Pregnancy and Breastfeeding",
        "text": "Female subject who is pregnant, breastfeeding or is considering becoming pregnant during the study or within 30 days after the last dose of study drug.",
        "instanceType": "EligibilityCriterionItem"
      },
      {
        "id": "eci_22",
        "name": "Laboratory Values",
        "text": "Laboratory values meeting the following criteria within the Screening period: AST/ALT > 2 x ULN; GFR < 40 mL/min/1.73m2; WBC < 2,500/μL; ANC < 1,500/μL; Platelet count < 100,000/μL; ALC < 800/μL; Hemoglobin < 10 g/dL.",
        "instanceType": "EligibilityCriterionItem"
      },
      {
        "id": "eci_23",
        "name": "Other Skin Disease",
        "text": "Active skin disease other than psoriasis that would interfere with the assessment of psoriasis.",
        "instanceType": "EligibilityCriterionItem"
      },
      {
        "id": "eci_24",
        "name": "Extra-articular Manifestations",
        "text": "Subject with extra-articular manifestations of PsA (e.g., PsO, uveitis, or IBD) that are not clinically stable for at least 30 days prior to study entry.",
        "instanceType": "EligibilityCriterionItem"
      },
      {
        "id": "eci_25",
        "name": "Joint Surgery or Injections",
        "text": "Subject has had joint surgery at joints to be assessed within this study or has been treated with intra-articular, intramuscular, intravenous, trigger point or tender point, intra-bursa, or intra-tendon sheath corticosteroids in the preceding 8 weeks prior to the Baseline visit.",
        "instanceType": "EligibilityCriterionItem"
      },
      {
        "id": "eci_26",
        "name": "Investigator Discretion",
        "text": "Consideration by the Investigator, for any reason, that the subject is an unsuitable candidate to receive upadacitinib.",
        "instanceType": "EligibilityCriterionItem"
      }
    ],
    "eligibilityCriteria": [
      {
        "id": "ec_1",
        "identifier": "1",
        "category": {
          "code": "Inclusion",
          "codeSystem": "USDM",
          "decode": "Inclusion"
        },
        "criterionItemId": "eci_1",
        "instanceType": "EligibilityCriterion",
        "name": "Age requirement",
        "nextId": "ec_2"
      },
      {
        "id": "ec_2",
        "identifier": "2",
        "category": {
          "code": "Inclusion",
          "codeSystem": "USDM",
          "decode": "Inclusion"
        },
        "criterionItemId": "eci_2",
        "instanceType": "EligibilityCriterion",
        "name": "PsA Diagnosis and CASPAR",
        "previousId": "ec_1",
        "nextId": "ec_3"
      },
      {
        "id": "ec_3",
        "identifier": "3",
        "category": {
          "code": "Inclusion",
          "codeSystem": "USDM",
          "decode": "Inclusion"
        },
        "criterionItemId": "eci_3",
        "instanceType": "EligibilityCriterion",
        "name": "Active Disease at Baseline",
        "previousId": "ec_2",
        "nextId": "ec_4"
      },
      {
        "id": "ec_4",
        "identifier": "4",
        "category": {
          "code": "Inclusion",
          "codeSystem": "USDM",
          "decode": "Inclusion"
        },
        "criterionItemId": "eci_4",
        "instanceType": "EligibilityCriterion",
        "name": "Plaque Psoriasis History",
        "previousId": "ec_3",
        "nextId": "ec_5"
      },
      {
        "id": "ec_5",
        "identifier": "5",
        "category": {
          "code": "Inclusion",
          "codeSystem": "USDM",
          "decode": "Inclusion"
        },
        "criterionItemId": "eci_5",
        "instanceType": "EligibilityCriterion",
        "name": "bDMARD Inadequate Response",
        "previousId": "ec_4",
        "nextId": "ec_6"
      },
      {
        "id": "ec_6",
        "identifier": "6",
        "category": {
          "code": "Inclusion",
          "codeSystem": "USDM",
          "decode": "Inclusion"
        },
        "criterionItemId": "eci_6",
        "instanceType": "EligibilityCriterion",
        "name": "bDMARD Discontinuation",
        "previousId": "ec_5",
        "nextId": "ec_7"
      },
      {
        "id": "ec_7",
        "identifier": "7",
        "category": {
          "code": "Inclusion",
          "codeSystem": "USDM",
          "decode": "Inclusion"
        },
        "criterionItemId": "eci_7",
        "instanceType": "EligibilityCriterion",
        "name": "Concomitant non-biologic DMARDs",
        "previousId": "ec_6",
        "nextId": "ec_8"
      },
      {
        "id": "ec_8",
        "identifier": "8",
        "category": {
          "code": "Inclusion",
          "codeSystem": "USDM",
          "decode": "Inclusion"
        },
        "criterionItemId": "eci_8",
        "instanceType": "EligibilityCriterion",
        "name": "Stable NSAIDs/Corticosteroids",
        "previousId": "ec_7",
        "nextId": "ec_9"
      },
      {
        "id": "ec_9",
        "identifier": "9",
        "category": {
          "code": "Inclusion",
          "codeSystem": "USDM",
          "decode": "Inclusion"
        },
        "criterionItemId": "eci_9",
        "instanceType": "EligibilityCriterion",
        "name": "Opiate and TCM Discontinuation",
        "previousId": "ec_8",
        "nextId": "ec_10"
      },
      {
        "id": "ec_10",
        "identifier": "10",
        "category": {
          "code": "Inclusion",
          "codeSystem": "USDM",
          "decode": "Inclusion"
        },
        "criterionItemId": "eci_10",
        "instanceType": "EligibilityCriterion",
        "name": "Pregnancy Test",
        "previousId": "ec_9",
        "nextId": "ec_11"
      },
      {
        "id": "ec_11",
        "identifier": "11",
        "category": {
          "code": "Inclusion",
          "codeSystem": "USDM",
          "decode": "Inclusion"
        },
        "criterionItemId": "eci_11",
        "instanceType": "EligibilityCriterion",
        "name": "Contraception Requirement",
        "previousId": "ec_10",
        "nextId": "ec_12"
      },
      {
        "id": "ec_12",
        "identifier": "12",
        "category": {
          "code": "Inclusion",
          "codeSystem": "USDM",
          "decode": "Inclusion"
        },
        "criterionItemId": "eci_12",
        "instanceType": "EligibilityCriterion",
        "name": "Informed Consent",
        "previousId": "ec_11"
      },
      {
        "id": "ec_13",
        "identifier": "1",
        "category": {
          "code": "Exclusion",
          "codeSystem": "USDM",
          "decode": "Exclusion"
        },
        "criterionItemId": "eci_13",
        "instanceType": "EligibilityCriterion",
        "name": "JAK Inhibitor Exposure",
        "nextId": "ec_14"
      },
      {
        "id": "ec_14",
        "identifier": "2",
        "category": {
          "code": "Exclusion",
          "codeSystem": "USDM",
          "decode": "Exclusion"
        },
        "criterionItemId": "eci_14",
        "instanceType": "EligibilityCriterion",
        "name": "Excessive DMARDs",
        "previousId": "ec_13",
        "nextId": "ec_15"
      },
      {
        "id": "ec_15",
        "identifier": "3",
        "category": {
          "code": "Exclusion",
          "codeSystem": "USDM",
          "decode": "Exclusion"
        },
        "criterionItemId": "eci_15",
        "instanceType": "EligibilityCriterion",
        "name": "Investigational Drug Use",
        "previousId": "ec_14",
        "nextId": "ec_16"
      },
      {
        "id": "ec_16",
        "identifier": "4",
        "category": {
          "code": "Exclusion",
          "codeSystem": "USDM",
          "decode": "Exclusion"
        },
        "criterionItemId": "eci_16",
        "instanceType": "EligibilityCriterion",
        "name": "Infection History",
        "previousId": "ec_15",
        "nextId": "ec_17"
      },
      {
        "id": "ec_17",
        "identifier": "5",
        "category": {
          "code": "Exclusion",
          "codeSystem": "USDM",
          "decode": "Exclusion"
        },
        "criterionItemId": "eci_17",
        "instanceType": "EligibilityCriterion",
        "name": "Underlying Medical Diseases",
        "previousId": "ec_16",
        "nextId": "ec_18"
      },
      {
        "id": "ec_18",
        "identifier": "6",
        "category": {
          "code": "Exclusion",
          "codeSystem": "USDM",
          "decode": "Exclusion"
        },
        "criterionItemId": "eci_18",
        "instanceType": "EligibilityCriterion",
        "name": "Psoriasis Treatments",
        "previousId": "ec_17",
        "nextId": "ec_19"
      },
      {
        "id": "ec_19",
        "identifier": "11",
        "category": {
          "code": "Exclusion",
          "codeSystem": "USDM",
          "decode": "Exclusion"
        },
        "criterionItemId": "eci_19",
        "instanceType": "EligibilityCriterion",
        "name": "Other Inflammatory Diseases",
        "previousId": "ec_18",
        "nextId": "ec_20"
      },
      {
        "id": "ec_20",
        "identifier": "12",
        "category": {
          "code": "Exclusion",
          "codeSystem": "USDM",
          "decode": "Exclusion"
        },
        "criterionItemId": "eci_20",
        "instanceType": "EligibilityCriterion",
        "name": "Drug or Alcohol Abuse",
        "previousId": "ec_19",
        "nextId": "ec_21"
      },
      {
        "id": "ec_21",
        "identifier": "13",
        "category": {
          "code": "Exclusion",
          "codeSystem": "USDM",
          "decode": "Exclusion"
        },
        "criterionItemId": "eci_21",
        "instanceType": "EligibilityCriterion",
        "name": "Pregnancy and Breastfeeding",
        "previousId": "ec_20",
        "nextId": "ec_22"
      },
      {
        "id": "ec_22",
        "identifier": "14",
        "category": {
          "code": "Exclusion",
          "codeSystem": "USDM",
          "decode": "Exclusion"
        },
        "criterionItemId": "eci_22",
        "instanceType": "EligibilityCriterion",
        "name": "Laboratory Values",
        "previousId": "ec_21",
        "nextId": "ec_23"
      },
      {
        "id": "ec_23",
        "identifier": "15",
        "category": {
          "code": "Exclusion",
          "codeSystem": "USDM",
          "decode": "Exclusion"
        },
        "criterionItemId": "eci_23",
        "instanceType": "EligibilityCriterion",
        "name": "Other Skin Disease",
        "previousId": "ec_22",
        "nextId": "ec_24"
      },
      {
        "id": "ec_24",
        "identifier": "16",
        "category": {
          "code": "Exclusion",
          "codeSystem": "USDM",
          "decode": "Exclusion"
        },
        "criterionItemId": "eci_24",
        "instanceType": "EligibilityCriterion",
        "name": "Extra-articular Manifestations",
        "previousId": "ec_23",
        "nextId": "ec_25"
      },
      {
        "id": "ec_25",
        "identifier": "17",
        "category": {
          "code": "Exclusion",
          "codeSystem": "USDM",
          "decode": "Exclusion"
        },
        "criterionItemId": "eci_25",
        "instanceType": "EligibilityCriterion",
        "name": "Joint Surgery or Injections",
        "previousId": "ec_24",
        "nextId": "ec_26"
      },
      {
        "id": "ec_26",
        "identifier": "18",
        "category": {
          "code": "Exclusion",
          "codeSystem": "USDM",
          "decode": "Exclusion"
        },
        "criterionItemId": "eci_26",
        "instanceType": "EligibilityCriterion",
        "name": "Investigator Discretion",
        "previousId": "ec_25"
      }
    ],
    "summary": {
      "inclusionCount": 12,
      "exclusionCount": 14,
      "totalCount": 26
    },
    "population": {
      "id": "pop_1",
      "name": "Study Population",
      "includesHealthySubjects": false,
      "criterionIds": [
        "ec_1",
        "ec_2",
        "ec_3",
        "ec_4",
        "ec_5",
        "ec_6",
        "ec_7",
        "ec_8",
        "ec_9",
        "ec_10",
        "ec_11",
        "ec_12",
        "ec_13",
        "ec_14",
        "ec_15",
        "ec_16",
        "ec_17",
        "ec_18",
        "ec_19",
        "ec_20",
        "ec_21",
        "ec_22",
        "ec_23",
        "ec_24",
        "ec_25",
        "ec_26"
      ],
      "instanceType": "StudyDesignPopulation",
      "description": "Target population defined by eligibility criteria"
    }
  },
  "rawResponse": {
    "eligibilityCriteria": [
      {
        "id": "ec_1",
        "name": "Age requirement",
        "identifier": "1",
        "category": {
          "code": "Inclusion",
          "codeSystem": "http://www.cdisc.org/USDM/criterionCategory",
          "decode": "Inclusion Criterion"
        },
        "criterionItemId": "eci_1",
        "instanceType": "EligibilityCriterion"
      },
      {
        "id": "ec_2",
        "name": "PsA Diagnosis and CASPAR",
        "identifier": "2",
        "category": {
          "code": "Inclusion",
          "codeSystem": "http://www.cdisc.org/USDM/criterionCategory",
          "decode": "Inclusion Criterion"
        },
        "criterionItemId": "eci_2",
        "instanceType": "EligibilityCriterion"
      },
      {
        "id": "ec_3",
        "name": "Active Disease at Baseline",
        "identifier": "3",
        "category": {
          "code": "Inclusion",
          "codeSystem": "http://www.cdisc.org/USDM/criterionCategory",
          "decode": "Inclusion Criterion"
        },
        "criterionItemId": "eci_3",
        "instanceType": "EligibilityCriterion"
      },
      {
        "id": "ec_4",
        "name": "Plaque Psoriasis History",
        "identifier": "4",
        "category": {
          "code": "Inclusion",
          "codeSystem": "http://www.cdisc.org/USDM/criterionCategory",
          "decode": "Inclusion Criterion"
        },
        "criterionItemId": "eci_4",
        "instanceType": "EligibilityCriterion"
      },
      {
        "id": "ec_5",
        "name": "bDMARD Inadequate Response",
        "identifier": "5",
        "category": {
          "code": "Inclusion",
          "codeSystem": "http://www.cdisc.org/USDM/criterionCategory",
          "decode": "Inclusion Criterion"
        },
        "criterionItemId": "eci_5",
        "instanceType": "EligibilityCriterion"
      },
      {
        "id": "ec_6",
        "name": "bDMARD Discontinuation",
        "identifier": "6",
        "category": {
          "code": "Inclusion",
          "codeSystem": "http://www.cdisc.org/USDM/criterionCategory",
          "decode": "Inclusion Criterion"
        },
        "criterionItemId": "eci_6",
        "instanceType": "EligibilityCriterion"
      },
      {
        "id": "ec_7",
        "name": "Concomitant non-biologic DMARDs",
        "identifier": "7",
        "category": {
          "code": "Inclusion",
          "codeSystem": "http://www.cdisc.org/USDM/criterionCategory",
          "decode": "Inclusion Criterion"
        },
        "criterionItemId": "eci_7",
        "instanceType": "EligibilityCriterion"
      },
      {
        "id": "ec_8",
        "name": "Stable NSAIDs/Corticosteroids",
        "identifier": "8",
        "category": {
          "code": "Inclusion",
          "codeSystem": "http://www.cdisc.org/USDM/criterionCategory",
          "decode": "Inclusion Criterion"
        },
        "criterionItemId": "eci_8",
        "instanceType": "EligibilityCriterion"
      },
      {
        "id": "ec_9",
        "name": "Opiate and TCM Discontinuation",
        "identifier": "9",
        "category": {
          "code": "Inclusion",
          "codeSystem": "http://www.cdisc.org/USDM/criterionCategory",
          "decode": "Inclusion Criterion"
        },
        "criterionItemId": "eci_9",
        "instanceType": "EligibilityCriterion"
      },
      {
        "id": "ec_10",
        "name": "Pregnancy Test",
        "identifier": "10",
        "category": {
          "code": "Inclusion",
          "codeSystem": "http://www.cdisc.org/USDM/criterionCategory",
          "decode": "Inclusion Criterion"
        },
        "criterionItemId": "eci_10",
        "instanceType": "EligibilityCriterion"
      },
      {
        "id": "ec_11",
        "name": "Contraception Requirement",
        "identifier": "11",
        "category": {
          "code": "Inclusion",
          "codeSystem": "http://www.cdisc.org/USDM/criterionCategory",
          "decode": "Inclusion Criterion"
        },
        "criterionItemId": "eci_11",
        "instanceType": "EligibilityCriterion"
      },
      {
        "id": "ec_12",
        "name": "Informed Consent",
        "identifier": "12",
        "category": {
          "code": "Inclusion",
          "codeSystem": "http://www.cdisc.org/USDM/criterionCategory",
          "decode": "Inclusion Criterion"
        },
        "criterionItemId": "eci_12",
        "instanceType": "EligibilityCriterion"
      },
      {
        "id": "ec_13",
        "name": "JAK Inhibitor Exposure",
        "identifier": "1",
        "category": {
          "code": "Exclusion",
          "codeSystem": "http://www.cdisc.org/USDM/criterionCategory",
          "decode": "Exclusion Criterion"
        },
        "criterionItemId": "eci_13",
        "instanceType": "EligibilityCriterion"
      },
      {
        "id": "ec_14",
        "name": "Excessive DMARDs",
        "identifier": "2",
        "category": {
          "code": "Exclusion",
          "codeSystem": "http://www.cdisc.org/USDM/criterionCategory",
          "decode": "Exclusion Criterion"
        },
        "criterionItemId": "eci_14",
        "instanceType": "EligibilityCriterion"
      },
      {
        "id": "ec_15",
        "name": "Investigational Drug Use",
        "identifier": "3",
        "category": {
          "code": "Exclusion",
          "codeSystem": "http://www.cdisc.org/USDM/criterionCategory",
          "decode": "Exclusion Criterion"
        },
        "criterionItemId": "eci_15",
        "instanceType": "EligibilityCriterion"
      },
      {
        "id": "ec_16",
        "name": "Infection History",
        "identifier": "4",
        "category": {
          "code": "Exclusion",
          "codeSystem": "http://www.cdisc.org/USDM/criterionCategory",
          "decode": "Exclusion Criterion"
        },
        "criterionItemId": "eci_16",
        "instanceType": "EligibilityCriterion"
      },
      {
        "id": "ec_17",
        "name": "Underlying Medical Diseases",
        "identifier": "5",
        "category": {
          "code": "Exclusion",
          "codeSystem": "http://www.cdisc.org/USDM/criterionCategory",
          "decode": "Exclusion Criterion"
        },
        "criterionItemId": "eci_17",
        "instanceType": "EligibilityCriterion"
      },
      {
        "id": "ec_18",
        "name": "Psoriasis Treatments",
        "identifier": "6",
        "category": {
          "code": "Exclusion",
          "codeSystem": "http://www.cdisc.org/USDM/criterionCategory",
          "decode": "Exclusion Criterion"
        },
        "criterionItemId": "eci_18",
        "instanceType": "EligibilityCriterion"
      },
      {
        "id": "ec_19",
        "name": "Other Inflammatory Diseases",
        "identifier": "11",
        "category": {
          "code": "Exclusion",
          "codeSystem": "http://www.cdisc.org/USDM/criterionCategory",
          "decode": "Exclusion Criterion"
        },
        "criterionItemId": "eci_19",
        "instanceType": "EligibilityCriterion"
      },
      {
        "id": "ec_20",
        "name": "Drug or Alcohol Abuse",
        "identifier": "12",
        "category": {
          "code": "Exclusion",
          "codeSystem": "http://www.cdisc.org/USDM/criterionCategory",
          "decode": "Exclusion Criterion"
        },
        "criterionItemId": "eci_20",
        "instanceType": "EligibilityCriterion"
      },
      {
        "id": "ec_21",
        "name": "Pregnancy and Breastfeeding",
        "identifier": "13",
        "category": {
          "code": "Exclusion",
          "codeSystem": "http://www.cdisc.org/USDM/criterionCategory",
          "decode": "Exclusion Criterion"
        },
        "criterionItemId": "eci_21",
        "instanceType": "EligibilityCriterion"
      },
      {
        "id": "ec_22",
        "name": "Laboratory Values",
        "identifier": "14",
        "category": {
          "code": "Exclusion",
          "codeSystem": "http://www.cdisc.org/USDM/criterionCategory",
          "decode": "Exclusion Criterion"
        },
        "criterionItemId": "eci_22",
        "instanceType": "EligibilityCriterion"
      },
      {
        "id": "ec_23",
        "name": "Other Skin Disease",
        "identifier": "15",
        "category": {
          "code": "Exclusion",
          "codeSystem": "http://www.cdisc.org/USDM/criterionCategory",
          "decode": "Exclusion Criterion"
        },
        "criterionItemId": "eci_23",
        "instanceType": "EligibilityCriterion"
      },
      {
        "id": "ec_24",
        "name": "Extra-articular Manifestations",
        "identifier": "16",
        "category": {
          "code": "Exclusion",
          "codeSystem": "http://www.cdisc.org/USDM/criterionCategory",
          "decode": "Exclusion Criterion"
        },
        "criterionItemId": "eci_24",
        "instanceType": "EligibilityCriterion"
      },
      {
        "id": "ec_25",
        "name": "Joint Surgery or Injections",
        "identifier": "17",
        "category": {
          "code": "Exclusion",
          "codeSystem": "http://www.cdisc.org/USDM/criterionCategory",
          "decode": "Exclusion Criterion"
        },
        "criterionItemId": "eci_25",
        "instanceType": "EligibilityCriterion"
      },
      {
        "id": "ec_26",
        "name": "Investigator Discretion",
        "identifier": "18",
        "category": {
          "code": "Exclusion",
          "codeSystem": "http://www.cdisc.org/USDM/criterionCategory",
          "decode": "Exclusion Criterion"
        },
        "criterionItemId": "eci_26",
        "instanceType": "EligibilityCriterion"
      }
    ],
    "eligibilityCriterionItems": [
      {
        "id": "eci_1",
        "name": "Age requirement",
        "text": "Adult male or female, at least ≥ 18 years old at Screening.",
        "instanceType": "EligibilityCriterionItem"
      },
      {
        "id": "eci_2",
        "name": "PsA Diagnosis and CASPAR",
        "text": "Clinical diagnosis of PsA with symptom onset at least 6 months prior to the Screening Visit and fulfillment of the Classification Criteria for PsA (CASPAR).",
        "instanceType": "EligibilityCriterionItem"
      },
      {
        "id": "eci_3",
        "name": "Active Disease at Baseline",
        "text": "Subject has active disease at Baseline defined as ≥ 3 tender joints (based on 68 joint counts) and ≥ 3 swollen joints (based on 66 joint counts) at Screening and Baseline Visits.",
        "instanceType": "EligibilityCriterionItem"
      },
      {
        "id": "eci_4",
        "name": "Plaque Psoriasis History",
        "text": "Diagnosis of active plaque psoriasis or documented history of plaque psoriasis.",
        "instanceType": "EligibilityCriterionItem"
      },
      {
        "id": "eci_5",
        "name": "bDMARD Inadequate Response",
        "text": "Subject has had an inadequate response (lack of efficacy after a minimum 12 week duration of therapy) or intolerance to treatment with at least 1 bDMARD.",
        "instanceType": "EligibilityCriterionItem"
      },
      {
        "id": "eci_6",
        "name": "bDMARD Discontinuation",
        "text": "Subjects must have discontinued all bDMARDs prior to the first dose of study drug. Subjects who need to discontinue bDMARDs prior to the Baseline Visit to comply with this inclusion criterion must follow the procedure specified below or at least five times the mean terminal elimination half-life of a drug: ≥ 4 weeks for etanercept; ≥ 8 weeks for adalimumab, infliximab, certolizumab, golimumab, abatacept, tocilizumab, and ixekizumab; ≥ 16 weeks for secukinumab; ≥ 12 weeks for ustekinumab; ≥ 1 year for rituximab OR ≥ 6 months if B cells have returned to pretreatment level or normal reference range (local lab) if pretreatment levels are not available.",
        "instanceType": "EligibilityCriterionItem"
      },
      {
        "id": "eci_7",
        "name": "Concomitant non-biologic DMARDs",
        "text": "Subject who is on current treatment with concomitant non-biologic DMARDs at study entry must be on ≤ 2 non-biologic DMARDs (except the combination of MTX and leflunomide) at the following doses: MTX (≤ 25 mg/week), SSZ (≤3000 mg/day), leflunomide (LEF) (≤20 mg/day), apremilast (≤60 mg/day), HCQ (≤ 400 mg/day), bucillamine (≤300 mg/day) and iguratimod (≤50 mg/day) for ≥ 12 weeks and at stable dose for ≥4 weeks prior to the Baseline Visit. No other DMARDs are permitted during the study.",
        "instanceType": "EligibilityCriterionItem"
      },
      {
        "id": "eci_8",
        "name": "Stable NSAIDs/Corticosteroids",
        "text": "Stable doses of NSAIDs, acetaminophen/paracetamol, low-potency opiates (tramadol or combination of acetaminophen and codeine or hydrocodone), oral corticosteroids (equivalent to prednisone ≤ 10 mg/day), or inhaled corticosteroids for stable medical conditions are allowed, but must have been at a stable dose for ≥1 weeks prior to the Baseline Visit.",
        "instanceType": "EligibilityCriterionItem"
      },
      {
        "id": "eci_9",
        "name": "Opiate and TCM Discontinuation",
        "text": "Subjects must have discontinued all opiates (except for tramadol or combination of acetaminophen and codeine or hydrocodone) at least 1 week and oral Traditional Chinese Medicine for at least 4 weeks prior to the first dose of study drug.",
        "instanceType": "EligibilityCriterionItem"
      },
      {
        "id": "eci_10",
        "name": "Pregnancy Test",
        "text": "Women of childbearing potential, must not have a positive serum pregnancy test at the Screening Visit and must have a negative urine pregnancy test at the Baseline Visit prior to study drug dosing.",
        "instanceType": "EligibilityCriterionItem"
      },
      {
        "id": "eci_11",
        "name": "Contraception Requirement",
        "text": "If female, subject must be postmenopausal OR permanently surgically sterile OR for Women of Childbearing Potential practicing at least one protocol specified method of birth control, that is effective from the Baseline visit through at least 30 days after the last dose of study drug.",
        "instanceType": "EligibilityCriterionItem"
      },
      {
        "id": "eci_12",
        "name": "Informed Consent",
        "text": "Subjects must voluntarily sign and date an informed consent, approved by an Independent Ethics Committee (IEC)/Institutional Review Board (IRB), prior to the initiation of any screening or study-specific procedures.",
        "instanceType": "EligibilityCriterionItem"
      },
      {
        "id": "eci_13",
        "name": "JAK Inhibitor Exposure",
        "text": "Prior exposure to any Janus Kinase (JAK) inhibitor (including but not limited to ruxolitinib, tofacitinib, baricitinib, and filgotinib).",
        "instanceType": "EligibilityCriterionItem"
      },
      {
        "id": "eci_14",
        "name": "Excessive DMARDs",
        "text": "Current treatment with > 2 non-biologic DMARDs or use of DMARDs other than MTX, SSZ, LEF, apremilast, HCQ, bucillamine or iguratimod or use of MTX in combination with LEF at Baseline.",
        "instanceType": "EligibilityCriterionItem"
      },
      {
        "id": "eci_15",
        "name": "Investigational Drug Use",
        "text": "Has been treated with any investigational drug within 30 days or five half-lives of the drug (whichever is longer) prior to the first dose of study drug or is currently enrolled in another interventional clinical study.",
        "instanceType": "EligibilityCriterionItem"
      },
      {
        "id": "eci_16",
        "name": "Infection History",
        "text": "Current or past history of infection including: History of recurrent or disseminated (even a single episode) herpes zoster; History of disseminated (even a single episode) herpes simplex; History of known invasive infection (e.g., listeriosis and histoplasmosis); Active human immunodeficiency virus (HIV) or immunodeficiency syndrome; Subject has active TB or meets TB exclusionary parameters; Active infection(s) requiring treatment with parenteral anti-infectives within 30 days, or oral anti-infectives within 14 days prior to the Baseline Visit; Chronic recurring infection and/or active viral infection; Active HBV or HCV.",
        "instanceType": "EligibilityCriterionItem"
      },
      {
        "id": "eci_17",
        "name": "Underlying Medical Diseases",
        "text": "Underlying medical diseases or problems including but not limited to: History of cardiovascular conditions (recent CVA, MI, stenting, uncontrolled hypertension); Organ transplant recipient; History of gastrointestinal perforation, diverticulitis; Conditions interfering with drug absorption; History of malignancy except NMSC or CIS of cervix; Clinically significant medical conditions; Wheelchair-bound or bedridden.",
        "instanceType": "EligibilityCriterionItem"
      },
      {
        "id": "eci_18",
        "name": "Psoriasis Treatments",
        "text": "Use of concomitant psoriasis treatments within specified timeframe: Phototherapy (4 weeks), Laser therapy (4 weeks), Topical psoriasis treatments (2 weeks).",
        "instanceType": "EligibilityCriterionItem"
      },
      {
        "id": "eci_19",
        "name": "Other Inflammatory Diseases",
        "text": "History of fibromyalgia, any arthritis with onset prior to age 17 years, or current diagnosis of inflammatory joint disease other than PsA (including, but not limited to rheumatoid arthritis, gout, overlap connective tissue diseases, scleroderma, polymyositis, dermatomyositis, systemic lupus erythematosus).",
        "instanceType": "EligibilityCriterionItem"
      },
      {
        "id": "eci_20",
        "name": "Drug or Alcohol Abuse",
        "text": "History of clinically significant (per Investigator's judgment) drug or alcohol abuse within the last 6 months preceding the Baseline Visit.",
        "instanceType": "EligibilityCriterionItem"
      },
      {
        "id": "eci_21",
        "name": "Pregnancy and Breastfeeding",
        "text": "Female subject who is pregnant, breastfeeding or is considering becoming pregnant during the study or within 30 days after the last dose of study drug.",
        "instanceType": "EligibilityCriterionItem"
      },
      {
        "id": "eci_22",
        "name": "Laboratory Values",
        "text": "Laboratory values meeting the following criteria within the Screening period: AST/ALT > 2 x ULN; GFR < 40 mL/min/1.73m2; WBC < 2,500/μL; ANC < 1,500/μL; Platelet count < 100,000/μL; ALC < 800/μL; Hemoglobin < 10 g/dL.",
        "instanceType": "EligibilityCriterionItem"
      },
      {
        "id": "eci_23",
        "name": "Other Skin Disease",
        "text": "Active skin disease other than psoriasis that would interfere with the assessment of psoriasis.",
        "instanceType": "EligibilityCriterionItem"
      },
      {
        "id": "eci_24",
        "name": "Extra-articular Manifestations",
        "text": "Subject with extra-articular manifestations of PsA (e.g., PsO, uveitis, or IBD) that are not clinically stable for at least 30 days prior to study entry.",
        "instanceType": "EligibilityCriterionItem"
      },
      {
        "id": "eci_25",
        "name": "Joint Surgery or Injections",
        "text": "Subject has had joint surgery at joints to be assessed within this study or has been treated with intra-articular, intramuscular, intravenous, trigger point or tender point, intra-bursa, or intra-tendon sheath corticosteroids in the preceding 8 weeks prior to the Baseline visit.",
        "instanceType": "EligibilityCriterionItem"
      },
      {
        "id": "eci_26",
        "name": "Investigator Discretion",
        "text": "Consideration by the Investigator, for any reason, that the subject is an unsuitable candidate to receive upadacitinib.",
        "instanceType": "EligibilityCriterionItem"
      }
    ],
    "population": {
      "id": "pop_1",
      "name": "Study Population",
      "includesHealthySubjects": false,
      "plannedEnrollmentNumber": {
        "maxValue": 630,
        "instanceType": "Range"
      },
      "plannedMinimumAge": "P18Y",
      "plannedSex": [
        {
          "code": "Male",
          "codeSystem": "http://www.cdisc.org/USDM/sex",
          "decode": "Male"
        },
        {
          "code": "Female",
          "codeSystem": "http://www.cdisc.org/USDM/sex",
          "decode": "Female"
        }
      ],
      "criterionIds": [
        "ec_1",
        "ec_2",
        "ec_3",
        "ec_4",
        "ec_5",
        "ec_6",
        "ec_7",
        "ec_8",
        "ec_9",
        "ec_10",
        "ec_11",
        "ec_12",
        "ec_13",
        "ec_14",
        "ec_15",
        "ec_16",
        "ec_17",
        "ec_18",
        "ec_19",
        "ec_20",
        "ec_21",
        "ec_22",
        "ec_23",
        "ec_24",
        "ec_25",
        "ec_26"
      ],
      "instanceType": "StudyDesignPopulation"
    }
  }
}